Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith A Ching

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|March 21, 2002
Large-scale analysis of the human and mouse transcriptomesAndrew I Su, Michael P Cooke, Keith A Ching, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 8, 2020
First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20<sup>+</sup> Non-Hodgkin LymphomasAjay K Gopal, Ronald Levy, Roch Houot, et al.
Nature Genetics|February 6, 2007
Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genomeNathaniel D Heintzman, Rhona K Stuart, Gary Hon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 24, 2013
Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinomaJennifer R Diamond, Ravi Salgia, Marileila Varella-Garcia, et al.
Molecular Cancer Therapeutics|January 7, 2012
An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735Kenneth E Hook, Scott J Garza, Maruja E Lira, et al.
Nature Medicine|December 11, 2021
Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trialThomas Powles, Srikala S Sridhar, Yohann Loriot, et al.
Molecular Cancer Therapeutics|October 11, 2013
Molecular predictors of sensitivity to the insulin-like growth factor 1 receptor inhibitor Figitumumab (CP-751,871)Adam Pavlicek, Maruja E Lira, Nathan V Lee, et al.
Cell Research|August 31, 2011
Dynamic chromatin states in human ES cells reveal potential regulatory sequences and genes involved in pluripotencyR David Hawkins, Gary C Hon, Chuhu Yang, et al.
Cancers|July 29, 2025
Blood-Epigenetic Biomarker Associations with Tumor Immunophenotype in Patients with Urothelial Carcinoma from JAVELIN Bladder 100Thomas Powles, Srikala S Sridhar, Joaquim Bellmunt, et al.
Nature|March 20, 2009
Histone modifications at human enhancers reflect global cell-type-specific gene expressionNathaniel D Heintzman, Gary C Hon, R David Hawkins, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Proceedings of the National Academy of Sciences of the United States of America|March 21, 2002
Large-scale analysis of the human and mouse transcriptomesAndrew I Su, Michael P Cooke, Keith A Ching, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 8, 2020
First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20<sup>+</sup> Non-Hodgkin LymphomasAjay K Gopal, Ronald Levy, Roch Houot, et al.
Nature Genetics|February 6, 2007
Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genomeNathaniel D Heintzman, Rhona K Stuart, Gary Hon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 24, 2013
Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinomaJennifer R Diamond, Ravi Salgia, Marileila Varella-Garcia, et al.
Molecular Cancer Therapeutics|January 7, 2012
An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735Kenneth E Hook, Scott J Garza, Maruja E Lira, et al.
Nature Medicine|December 11, 2021
Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trialThomas Powles, Srikala S Sridhar, Yohann Loriot, et al.
Molecular Cancer Therapeutics|October 11, 2013
Molecular predictors of sensitivity to the insulin-like growth factor 1 receptor inhibitor Figitumumab (CP-751,871)Adam Pavlicek, Maruja E Lira, Nathan V Lee, et al.
Cell Research|August 31, 2011
Dynamic chromatin states in human ES cells reveal potential regulatory sequences and genes involved in pluripotencyR David Hawkins, Gary C Hon, Chuhu Yang, et al.
Cancers|July 29, 2025
Blood-Epigenetic Biomarker Associations with Tumor Immunophenotype in Patients with Urothelial Carcinoma from JAVELIN Bladder 100Thomas Powles, Srikala S Sridhar, Joaquim Bellmunt, et al.
Nature|March 20, 2009
Histone modifications at human enhancers reflect global cell-type-specific gene expressionNathaniel D Heintzman, Gary C Hon, R David Hawkins, et al.
Pageof 3